---
document_datetime: 2025-12-29 12:22:47
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/anagrelide-viatris.html
document_name: anagrelide-viatris.html
version: success
processing_time: 0.1326678
conversion_datetime: 2025-12-29 22:14:29.401677
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Anagrelide Viatris (previously Anagrelide Mylan)

[RSS](/en/individual-human-medicine.xml/67131)

##### Authorised

This medicine is authorised for use in the European Union

anagrelide Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Anagrelide Viatris (previously Anagrelide Mylan)](#news-on)
- [More information on Anagrelide Mylan](#more-information-on-anagrelide-mylan-1545)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Anagrelide Viatris (previously Anagrelide Mylan). It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Anagrelide Viatris.

For practical information about using Anagrelide Viatris, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Anagrelide Mylan and what is it used for?

Anagrelide Mylan is a medicine used to reduce the number of platelets (components that help the blood to clot) in patients with essential thrombocythaemia (a disease in which there are too many platelets circulating in the blood). 'Essential' means that the disease has no obvious cause.

Anagrelide Mylan is used when the patient's current treatment does not work well enough or has unacceptable side effects, and when they are 'at risk' because of their age (over 60 years), very high platelet counts or previous clotting problems.

Anagrelide Mylan contains the active substance anagrelide and is a 'generic medicine'. This means that Anagrelide Mylan contains the same active substance and works in the same way as a 'reference medicine' already authorised in the European Union (EU) called Xagrid. Anagrelide Mylan is also a 'hybrid medicine' because it is available in an additional strength.

## How is Anagrelide Mylan used?

Anagrelide Mylan can only be obtained with a prescription. Treatment should only be started by a doctor who has experience in treating essential thrombocythaemia.

Anagrelide Mylan is available as capsules (0.5  and 1 mg). The recommended starting dose is one 0.5 mg capsule twice a day. After a week, the dose is increased every week by 0.5 mg a day, until the platelet count is below 600 million platelets per millilitre, and ideally between 150 and 400 million/ml (the level usually seen in healthy people). Results are normally seen within 2 or 3 weeks of starting treatment.

The maximum recommended dose of Anagrelide Mylan is 2.5 mg at a time.

## How does Anagrelide Mylan work?

Essential thrombocythaemia is a disease in which the bone marrow produces too many platelets. This puts the patient at risk of developing blood clots or bleeding problems. The active substance in Anagrelide Mylan, anagrelide, blocks the development and growth of cells in the bone marrow called 'megakaryocytes', which produce platelets. This reduces the platelet count, helping to improve symptoms in patients with the disease.

## How has Anagrelide Mylan been studied?

Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Xagrid, and do not need to be repeated for Anagrelide Mylan.

As for every medicine, the company provided studies on the quality of Anagrelide Mylan. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Anagrelide Mylan?

Because Anagrelide Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Anagrelide Mylan approved?

The European Medicines Agency concluded that, in accordance with EU requirements, Anagrelide Mylan has been shown to have comparable quality and to be bioequivalent to Xagrid. Therefore, the Agency's view was that, as for Xagrid, the benefit outweighs the identified risk. The Agency recommended that Anagrelide Mylan be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Anagrelide Mylan?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Anagrelide Mylan have been included in the summary of product characteristics and the package leaflet.

## Other information about Anagrelide Mylan

The European Commission granted a marketing authorisation valid throughout the European Union for Anagrelide Mylan on 15 February 2018.

For more information about treatment with Anagrelide Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Anagrelide Mylan : EPAR - Summary for the public

Reference Number: EMA/8115/2018

English (EN) (92.78 KB - PDF)

**First published:** 27/02/2018

**Last updated:** 27/02/2018

[View](/en/documents/overview/anagrelide-mylan-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-369)

български (BG) (117.32 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/bg/documents/overview/anagrelide-mylan-epar-summary-public_bg.pdf)

español (ES) (90.99 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/es/documents/overview/anagrelide-mylan-epar-summary-public_es.pdf)

čeština (CS) (115.57 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/cs/documents/overview/anagrelide-mylan-epar-summary-public_cs.pdf)

dansk (DA) (90.39 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/da/documents/overview/anagrelide-mylan-epar-summary-public_da.pdf)

Deutsch (DE) (92.49 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/de/documents/overview/anagrelide-mylan-epar-summary-public_de.pdf)

eesti keel (ET) (89.23 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/et/documents/overview/anagrelide-mylan-epar-summary-public_et.pdf)

ελληνικά (EL) (118.99 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/el/documents/overview/anagrelide-mylan-epar-summary-public_el.pdf)

français (FR) (92.21 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/fr/documents/overview/anagrelide-mylan-epar-summary-public_fr.pdf)

hrvatski (HR) (109.55 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/hr/documents/overview/anagrelide-mylan-epar-summary-public_hr.pdf)

italiano (IT) (89.46 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/it/documents/overview/anagrelide-mylan-epar-summary-public_it.pdf)

latviešu valoda (LV) (111.05 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/lv/documents/overview/anagrelide-mylan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (114.24 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/lt/documents/overview/anagrelide-mylan-epar-summary-public_lt.pdf)

magyar (HU) (111.8 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/hu/documents/overview/anagrelide-mylan-epar-summary-public_hu.pdf)

Malti (MT) (116.32 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/mt/documents/overview/anagrelide-mylan-epar-summary-public_mt.pdf)

Nederlands (NL) (91.08 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/nl/documents/overview/anagrelide-mylan-epar-summary-public_nl.pdf)

polski (PL) (116.17 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/pl/documents/overview/anagrelide-mylan-epar-summary-public_pl.pdf)

português (PT) (91.13 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/pt/documents/overview/anagrelide-mylan-epar-summary-public_pt.pdf)

română (RO) (112.13 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/ro/documents/overview/anagrelide-mylan-epar-summary-public_ro.pdf)

slovenčina (SK) (115.98 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/sk/documents/overview/anagrelide-mylan-epar-summary-public_sk.pdf)

slovenščina (SL) (109.96 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/sl/documents/overview/anagrelide-mylan-epar-summary-public_sl.pdf)

Suomi (FI) (89.5 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/fi/documents/overview/anagrelide-mylan-epar-summary-public_fi.pdf)

svenska (SV) (90.94 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

27/02/2018

[View](/sv/documents/overview/anagrelide-mylan-epar-summary-public_sv.pdf)

Anagrelide Mylan : EPAR - Risk management plan summary

English (EN) (97.06 KB - PDF)

**First published:** 11/05/2023

[View](/en/documents/rmp-summary/anagrelide-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Anagrelide Viatris : EPAR - Product Information

English (EN) (293.99 KB - PDF)

**First published:** 27/02/2018

**Last updated:** 14/11/2025

[View](/en/documents/product-information/anagrelide-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-143)

български (BG) (517.75 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/bg/documents/product-information/anagrelide-viatris-epar-product-information_bg.pdf)

español (ES) (381.21 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/es/documents/product-information/anagrelide-viatris-epar-product-information_es.pdf)

čeština (CS) (387.38 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/cs/documents/product-information/anagrelide-viatris-epar-product-information_cs.pdf)

dansk (DA) (448.8 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/da/documents/product-information/anagrelide-viatris-epar-product-information_da.pdf)

Deutsch (DE) (319.17 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/de/documents/product-information/anagrelide-viatris-epar-product-information_de.pdf)

eesti keel (ET) (291.69 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/et/documents/product-information/anagrelide-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (433.43 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/el/documents/product-information/anagrelide-viatris-epar-product-information_el.pdf)

français (FR) (333.9 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/fr/documents/product-information/anagrelide-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (488.7 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/hr/documents/product-information/anagrelide-viatris-epar-product-information_hr.pdf)

íslenska (IS) (432.94 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/is/documents/product-information/anagrelide-viatris-epar-product-information_is.pdf)

italiano (IT) (434.54 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/it/documents/product-information/anagrelide-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (348.06 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/lv/documents/product-information/anagrelide-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (448.52 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/lt/documents/product-information/anagrelide-viatris-epar-product-information_lt.pdf)

magyar (HU) (528.56 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/hu/documents/product-information/anagrelide-viatris-epar-product-information_hu.pdf)

Malti (MT) (562.17 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/mt/documents/product-information/anagrelide-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (448.22 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/nl/documents/product-information/anagrelide-viatris-epar-product-information_nl.pdf)

norsk (NO) (330.23 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/no/documents/product-information/anagrelide-viatris-epar-product-information_no.pdf)

polski (PL) (442.88 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/pl/documents/product-information/anagrelide-viatris-epar-product-information_pl.pdf)

português (PT) (344.75 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/pt/documents/product-information/anagrelide-viatris-epar-product-information_pt.pdf)

română (RO) (387.88 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/ro/documents/product-information/anagrelide-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (581.88 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/sk/documents/product-information/anagrelide-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (326.75 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/sl/documents/product-information/anagrelide-viatris-epar-product-information_sl.pdf)

Suomi (FI) (465.11 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/fi/documents/product-information/anagrelide-viatris-epar-product-information_fi.pdf)

svenska (SV) (335.17 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

14/11/2025

[View](/sv/documents/product-information/anagrelide-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000309803 14/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Anagrelide Viatris (previously Anagrelide Mylan) : EPAR - All Authorised presentations

English (EN) (37.74 KB - PDF)

**First published:** 27/02/2018

**Last updated:** 17/01/2024

[View](/en/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-616)

български (BG) (62.66 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/bg/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (38.87 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/es/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (40.35 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/cs/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (36.19 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/da/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (37.82 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/de/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (35.89 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/et/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (32.78 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/el/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (8.78 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/fr/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (63.97 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/hr/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (35.84 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/is/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (34.74 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/it/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (52.7 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/lv/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (82.56 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/lt/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (52.69 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/hu/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (27.2 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/mt/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (37.96 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/nl/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (31.19 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/no/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (28.8 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/pl/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (38.66 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/pt/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (58.99 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/ro/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (51.86 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/sk/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (37.31 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/sl/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (73.16 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/fi/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (68.53 KB - PDF)

**First published:**

27/02/2018

**Last updated:**

17/01/2024

[View](/sv/documents/all-authorised-presentations/anagrelide-viatris-previously-anagrelide-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Anagrelide Viatris (previously Anagrelide Mylan) Active substance anagrelide hydrochloride International non-proprietary name (INN) or common name anagrelide Therapeutic area (MeSH) Thrombocythemia, Essential Anatomical therapeutic chemical (ATC) code L01XX35

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Anagrelide Viatris is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.

## Authorisation details

EMA product number EMEA/H/C/004585

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Mulhuddart Dublin 15 Ireland

Opinion adopted 14/12/2017 Marketing authorisation issued 15/02/2018 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Anagrelide Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.29 KB - PDF)

**First published:** 03/03/2025

**Last updated:** 14/11/2025

[View](/en/documents/procedural-steps-after/anagrelide-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Anagrelide Viatris (previously Anagrelide Mylan) : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (133.21 KB - PDF)

**First published:** 25/04/2019

**Last updated:** 03/03/2025

[View](/en/documents/procedural-steps-after/anagrelide-viatris-previously-anagrelide-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Anagrelide Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/63484/2018

English (EN) (304.11 KB - PDF)

**First published:** 27/02/2018

**Last updated:** 27/02/2018

[View](/en/documents/assessment-report/anagrelide-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Anagrelide Mylan

Adopted

Reference Number: EMA/818102/2017

English (EN) (82.5 KB - PDF)

**First published:** 15/12/2017

**Last updated:** 15/12/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-anagrelide-mylan_en.pdf)

#### News on Anagrelide Viatris (previously Anagrelide Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2017) 15/12/2017

#### More information on Anagrelide Mylan

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-573)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 14/11/2025

## Share this page

[Back to top](#main-content)